Xeris Pharmaceuticals Valuation
| XERS Stock | USD 3.45 0.27 8.49% |
At this time, the company appears to be undervalued. Xeris Pharmaceuticals maintains a prevalent Real Value of $3.81 per share. The last-minute price of the company is $3.45. Our model calculates the value of Xeris Pharmaceuticals from examining the company fundamentals such as Return On Asset of -0.087, current valuation of 675.64 M, and Profit Margin of (0.34) % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Xeris Pharmaceuticals' valuation include:
Price Book 3.3354 | Enterprise Value 675.6 M | Enterprise Value Ebitda (3.36) | Price Sales 2.7451 | Enterprise Value Revenue 3.6061 |
Undervalued
Today
Please note that Xeris Pharmaceuticals' price fluctuation is moderately volatile at this time. Calculation of the real value of Xeris Pharmaceuticals is based on 3 months time horizon. Increasing Xeris Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Xeris stock is determined by what a typical buyer is willing to pay for full or partial control of Xeris Pharmaceuticals. Since Xeris Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Xeris Stock. However, Xeris Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.45 | Real 3.81 | Target 4.9 | Hype 3.49 |
The intrinsic value of Xeris Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Xeris Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Xeris Pharmaceuticals helps investors to forecast how Xeris stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Xeris Pharmaceuticals more accurately as focusing exclusively on Xeris Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Xeris Pharmaceuticals' intrinsic value based on its ongoing forecasts of Xeris Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Xeris Pharmaceuticals' closest peers.
Xeris Pharmaceuticals Cash |
|
Xeris Valuation Trend
Xeris Pharmaceuticals' real value is important for investors to make better decisions and a more accurate overall view of Xeris Pharmaceuticals' financial worth over time. Using both Xeris Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Xeris Revenue by Product
Xeris Pharmaceuticals Total Value Analysis
Xeris Pharmaceuticals is at this time projected to have valuation of 675.64 M with market capitalization of 514.33 M, debt of 229.19 M, and cash on hands of 111.55 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Xeris Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
675.64 M | 514.33 M | 229.19 M | 111.55 M |
Xeris Pharmaceuticals Investor Information
About 44.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 0.47. Xeris Pharmaceuticals had not issued any dividends in recent years. The entity had 1:1 split on the 6th of October 2021. Based on the key indicators related to Xeris Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Xeris Pharmaceuticals may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.Xeris Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Xeris Pharmaceuticals has an asset utilization ratio of 50.81 percent. This implies that the Company is making $0.51 for each dollar of assets. An increasing asset utilization means that Xeris Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Xeris Pharmaceuticals Ownership Allocation
Xeris Pharmaceuticals retains a total of 149.08 Million outstanding shares. 30% of Xeris Pharmaceuticals outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.Xeris Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 163.91 M. Net Loss for the year was (62.26 M) with profit before overhead, payroll, taxes, and interest of 87.61 M.About Xeris Pharmaceuticals Valuation
The stock valuation mechanism determines Xeris Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Xeris Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Xeris Pharmaceuticals. We calculate exposure to Xeris Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Xeris Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 135.3 M | 142 M | |
| Pretax Profit Margin | (0.39) | (0.41) | |
| Operating Profit Margin | (0.27) | (0.28) | |
| Net Loss | (0.38) | (0.40) | |
| Gross Profit Margin | 0.83 | 0.91 |
Xeris Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Xeris Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 137.7 M |
Xeris Pharmaceuticals Current Valuation Indicators
Xeris Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Xeris Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Xeris Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Xeris Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Xeris Pharmaceuticals' worth.Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.